logo
Dark Energy experiment challenges Einstein's theory of Universe

Dark Energy experiment challenges Einstein's theory of Universe

Yahoo19-03-2025

The mysterious force called Dark Energy, which drives the expansion of the Universe, might be changing in a way that challenges our current understanding of time and space, scientists have found.
Some of them believe that they may be on the verge of one of the biggest discoveries in astronomy for a generation - one that could force a fundamental rethink.
This early-stage finding is at odds with the current theory which was developed in part by Albert Einstein.
More data is needed to confirm these results, but even some of the most cautious and respected researchers involved in the study, such as Prof Ofer Lahav, from University College London, are being swept up by the mounting evidence.
"It is a dramatic moment," he told BBC News.
"We may be witnessing a paradigm shift in our understanding of the Universe."
The discovery of Dark Energy in 1998 was in itself shocking. Up until then the view had been that after the Big Bang, which created the Universe, its expansion would slow down under the force of gravity.
But observations by US and Australian scientists found that it was actually speeding up. They had no idea what the force driving this was, so they gave it a name signifying their lack of understanding - Dark Energy.
Although we don't know what Dark Energy is - it is one of the greatest mysteries in science - astronomers can measure it and whether it is changing by observing the acceleration of galaxies away from each other at different points in the history of the Universe.
Several experiments were built to find answers, including the Dark Energy Spectroscopic Instrument (DESI) at the Kit Peak National Observatory near Tucson Arizona. It consists of 5,000 optical fibres, each one of which is a robotically controlled telescope scanning galaxies at high speed.
Last year, when DESI researchers found hints that the force exerted by dark energy had changed over time, many scientists thought that it was a blip in the data which would go away.
Instead, a year on, that blip has grown.
"The evidence is stronger now than it was," said Prof Seshadri Nadathur at the University of Portsmouth
"We've also performed many additional tests compared to the first year, and they're making us confident that the results aren't driven by some unknown effect in the data that we haven't accounted for," he said.
The data has not yet passed the threshold of being described as a discovery, but has led many astronomers, such as Scotland's Astronomer Royal, Prof Catherine Heymans, of Edinburgh University, to sit up and take notice.
"Dark Energy appears to be even weirder than we thought," she told BBC News.
"In 2024 the data was quite new, no-one was quite sure of it and people thought more work needed to be done.
"But now, there's more data, and a lot of scrutiny by the scientific community, so, while there is still a chance that the 'blip' may go away, there's also a possibility that we might be edging to a really big discovery."
So what is causing the variation?
"No one knows!" Prof Lahav admits, cheerfully.
"If this new result is correct, then we need to find the mechanism that causes the variation and that might mean a brand new theory, which makes this so exciting."
DESI will continue to take more data over the next two years, with plans to measure roughly 50 million galaxies and other bright objects, in an effort to nail down whether their observations are unequivocally correct.
"We're in the business of letting the Universe tell us how it works, and maybe it is telling us it's more complicated than we thought it was," said Andrei Cuceu, a postdoctoral researcher at the Lawrence Berkeley National Lab, in California.
More details on the nature of Dark Energy will be obtained by the European Space Agency's (ESA) Euclid mission, a space telescope which will probe further than DESI and obtain even greater detail. It was launched in 2023 and ESA released the new images from the spacecraft today.
The DESI collaboration involves more than 900 researchers from more than 70 institutions, around the world, including Durham, UCL and Portsmouth University from the UK.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

Yahoo

time6 hours ago

  • Yahoo

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

Business Wire

time6 hours ago

  • Business Wire

Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia

BOSTON & SYDNEY--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. 'The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,' said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. 'Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry'. BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich.

Used in COVID shots, mRNA may help rid the body of HIV
Used in COVID shots, mRNA may help rid the body of HIV

Chicago Tribune

time6 hours ago

  • Chicago Tribune

Used in COVID shots, mRNA may help rid the body of HIV

The technology that powered COVID vaccines may also lead scientists to a cure for HIV. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary and so far has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of COVID vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting HIV. Dr. Sharon Lewin, director of the Doherty Institute at the University of Melbourne, who led the study, called mRNA a 'miraculous' tool 'to deliver things that you want into places that were not possible before.' Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. 'The fear right now is not rational,' Lewin said, adding that 'mRNA vaccines have been given to millions of people around the world, so we have a very good understanding of their risks.' The new study describes the use of mRNA as a tool to flush HIV out of its hiding places. Other uses could involve providing proteins missing from those with certain diseases or correcting genetic errors. Frauke Muecksch, a virologist at Heidelberg University in Germany who was not involved in the work, called mRNA a 'promising, absolutely powerful technology.' Although most people may have only heard of mRNA's use in science during the pandemic, scientists have been working with it for more than 20 years, she said. 'I think it's not just therapeutically very powerful, but also for basic science, for research, it opens up a lot of avenues,' she added. Potent antiretroviral drugs can now control HIV, suppressing it to undetectable levels. Still, minute amounts of the virus lie dormant in so-called reservoirs, waiting for an opportunity to resurge. A cure for HIV would involve ferreting out all of this virus and destroying it, a strategy that has been called 'shock and kill.' A significant hurdle is that the virus lies dormant in a particular type of immune cell, called a resting CD4 cell. Because these cells are inactive, they tend to be unresponsive to drugs. The few drugs scientists have previously used to rouse the virus in these cells were not specific to HIV and had unwanted side effects. 'It's fair to say the field's been a little bit stuck,' said Brad Jones, a viral immunologist at Weill Cornell Medicine who was not involved in the latest research. In 2022, Jones and his colleagues found that the immune boost from the mRNA vaccines awakened latent HIV in people living with the virus. (Other research has shown that mRNA vaccines also activated dormant viruses including Epstein Barr.) 'You get just a little bit of a gentle nudge with some of these vaccines, and it's enough to coax some of these latent viruses out so they can be killed,' Jones said. Lewin and her colleagues had for years experimented with other ways to activate HIV but had no luck in resting cells. Seeing the success of the COVID vaccines, which used lipid nanoparticles — tiny spheres of fat — containing mRNA, her team tested similar particles. They used the particles to deliver two different sets of molecules: Tat, which is adept at switching HIV on, and CRISPR, a tool that can 'edit' genes. The researchers showed that in resting immune cells from people living with HIV, the approach coaxed the virus out of dormancy. 'It's very, very hard to deal with these cells, so I think this really targeting the right population of cells is what makes this paper special,' Muecksch said. It's unclear whether the new approach can successfully awaken all of the dormant HIV in the body, and what side effects it might produce. Lewin said that 'mRNA will almost certainly have some adverse effects, as every drug does, but we will investigate that systematically, as we do for any new drug.' In this case, she said, side effects may be more acceptable to people living with HIV than having to take medications for the rest of their lives. The researchers plan to test the method in HIV-infected animals next, before moving into clinical trials. This article originally appeared in The New York Times.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store